Monitor shareholder votes and SEC effectiveness. The deal's success hinges on the $150M PIPE closing. If approved, INM stock will effectively represent a small fraction of the combined entity. Traders should consider the massive dilution and potential upside from the PIPE-funded pipeline.
INM drugs
INM drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 19 $1.60entry
- T+1 · 6mo ago +0.63%α −0.41% · $1.61
- T+5 · 6mo ago +5.63%α +3.38% · $1.69
- T+20 · 5mo ago −6.88%α −7.86% · $1.49
- T+60 · 3mo ago −10.63%α −16.92% · $1.43
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InMed Pharmaceuticals (INM) entered into a definitive reverse merger agreement with Mentari Therapeutics, where Mentari shareholders will receive a majority stake in the combined entity. A concurrent PIPE of at least $150 million will fund operations. Existing INM shareholders face massive dilution but receive contingent value rights. The deal transforms the company but substantially dilutes current holders.
Key Financial Metrics
Key Facts
- Reverse merger: Mentari Therapeutics merges with INM via a two-step process, with Mentari shareholders receiving majority ownership.
- Concurrent PIPE of at least $150 million from investors, including conversion of existing convertible notes.
- INM shareholders receive contingent value rights (CVRs) for future payments.
- Mentari equity value set at $125 million (excluding PIPE proceeds), with INM parent valuation capped at $10 million.
- Net cash adjustment formula for INM potentially reduces its valuation, with a base of negative $3.4 million.
- Deal subject to shareholder approvals, SEC registration, Nasdaq listing, and other conditions.
- Termination fee of $400,000 if INM takes a superior offer, and $4 million if Mentari fails to close.
Financial Impact
PIPE of at least $150 million; post-merger entity valuation implied in hundreds of millions, but existing INM shareholders heavily diluted.
Risk Factors
- Failure to raise minimum PIPE amount ($150M) could kill the deal.
- Regulatory or shareholder approval delays or denials.
- Massive dilution for existing INM shareholders reduces per-share value.
- Integration risks and execution of Mentari's pipeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001213900-26-058800 |
| Document: ea029148201ex10-5.htm | 0001213900-26-058800 |
| Document: ea029148201ex10-4.htm | 0001213900-26-058800 |
Track record
22 reports on INM
6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 10 of 12 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
- Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
- Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
- Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
- Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers